Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML).

Trial Profile

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Decitabine (Primary) ; Aclarubicin; Cytarabine; Granulocyte colony-stimulating factors
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top